Goal Motivation: Are You Chasing Your Dreams or Running From Your Fears?

Published Date: 08 Mar 2023

A new study from Edith Cowan University (ECU) has shown that understanding the following motivations can help find personal goals and prevent dementia.

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

Schizophrenia patients are motivated by music therapy.

Recommended Articles For You

Understanding QSOFA: A Vital Tool for Recognizing Sepsis  

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression 

Exploring New Treatment Options for Hemophilia: A Journey into the Unknown 

From Bruises to Blood Clots: Everything You Need to Know about Hematoma  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

2.

Prostate Cancer Treatment Associated With Long-Term Complications

3.

Early, virtual palliative care feasible for advanced lung cancer

4.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

5.

United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.

1.

Understanding the Importance of Knowing Your MCV Normal Range

2.

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies

3.

Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management

4.

Beyond the Battle: Navigating Life After Cancer

5.

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

2.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

3.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

5.

Navigating the Complexities of Ph Negative ALL - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot